Loading…
Lobbying Spend
—
Filings
12
Firms Hired
1
Active Period
2023–2025
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Kidney PATIENT Act of 2023
2024 · fourth_quarter · Firm: CROSSROADS STRATEGIES, LLC
General education about end stage renal disease (ESRD) and kidney disease policies, including Medicare beneficiary access to pharmaceuticals. H.R.5074, Kidney PATIENT Act of 2023; S.4510, A bill to amend the American Taxpayer Relief Act of 2012 to delay implementation of the inclusion of oral-only ESRD-related drugs in the Medicare ESRD prospective payment system.
Client expense: — · Firm income: $50,000
Matched citations: H.R.5074
Kidney PATIENT Act of 2023
2024 · third_quarter · Firm: CROSSROADS STRATEGIES, LLC
General education about end stage renal disease (ESRD) and kidney disease policies, including Medicare beneficiary access to pharmaceuticals. H.R.5074, Kidney PATIENT Act of 2023; S.4510, A bill to amend the American Taxpayer Relief Act of 2012 to delay implementation of the inclusion of oral-only ESRD-related drugs in the Medicare ESRD prospective payment system.
Client expense: — · Firm income: $50,000
Matched citations: H.R.5074
Kidney PATIENT Act of 2023
2024 · second_quarter · Firm: CROSSROADS STRATEGIES, LLC
General education about end stage renal disease (ESRD) and kidney disease policies, including Medicare beneficiary access to pharmaceuticals. H.R.5074, Kidney PATIENT Act of 2023; S.4510, A bill to amend the American Taxpayer Relief Act of 2012 to delay implementation of the inclusion of oral-only ESRD-related drugs in the Medicare ESRD prospective payment system.
Client expense: — · Firm income: $40,000
Matched citations: H.R.5074
Kidney PATIENT Act of 2023
2024 · first_quarter · Firm: CROSSROADS STRATEGIES, LLC
General education about end stage renal disease (ESRD) and kidney disease policies, including Medicare beneficiary access to pharmaceuticals. H.R.5074, Kidney PATIENT Act of 2023.
Client expense: — · Firm income: $40,000
Matched citations: H.R.5074
Kidney PATIENT Act of 2023
2023 · fourth_quarter · Firm: CROSSROADS STRATEGIES, LLC
General education about end stage renal disease (ESRD) and kidney disease policies, including Medicare beneficiary access to pharmaceuticals. H.R.5074, Kidney PATIENT Act of 2023.
Client expense: — · Firm income: $40,000
Matched citations: H.R.5074
Kidney PATIENT Act of 2023
2023 · third_quarter · Firm: CROSSROADS STRATEGIES, LLC
General education about end stage renal disease (ESRD) and kidney disease policies, including Medicare beneficiary access to pharmaceuticals. H.R.5074, Kidney PATIENT Act of 2023.
Client expense: — · Firm income: $40,000
Matched citations: H.R.5074
Source: Senate LDA